CLDN18.2 protein (His tag)
-
- Target
- CLDN18.2
- Protein Type
- Recombinant
- Origin
- Human
-
Source
- Escherichia coli (E. coli)
- Purification tag / Conjugate
- His tag
- Purpose
- Recombinant Human CLDN18.2(N-6His,C-Avi)
- Characteristics
- Biotinylated Recombinant Human CLDN18.2 is produced by our E.coli expression system and the targetgene encoding extracellular is expressed with a 6His tag at the N-terminus.
- Purity
- > 95 % as determined by reducing SDS-PAGE.
- Endotoxin Level
- < 1.0 EU per g as determined by the LAL method.
- Biological Activity Comment
- Test in progress
-
CLDN18.2 protein
Origin: Human Host: HEK-293 Cells Synthetic Nanodisc
CLDN18.2 protein-VLPOrigin: Human Host: HEK-293 Cells VLP
-
- Restrictions
- For Research Use only
-
- Format
- Frozen, Liquid
- Buffer
- Supplied as a 0.2 μm filtered solution of 20 mM Tris, 8M Urea,150 mM NaCl, 5 mM β-ME, pH 8.5.
- Storage
- -20 °C
- Storage Comment
- Store at < -20°C, stable for 6 months. Please minimize freeze-thaw cycles.
-
- Target
- CLDN18.2
- Background
-
Background: Claudin-18(CLDN18) is a protein that in humans is encoded by the CLDN18 gene. It belongs to the group of claudins. CLDN18 belongs to the large claudin family of proteins, which form tight junction strands in epithelial cells. CLDN18 plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity. CLDN18 has two isoform A1 and isoform A2.IMAB362 (Claudiximab) is a monoclonal antibody against isoform 2 of Claudin-18. It is underinvestigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. IMAB362 was developed by Ganymed Pharmaceuticals AG.
Synonym: Claudin-18.2, CLDN18
- Molecular Weight
- 12.6 kDa
-
